Osimertinib is the standard treatment of advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients and EGFR T790M-mediated resistance [1,2,3,4]. Here, EGFR is linked to non-small cell lung carcinoma.